Department of Biomedical Engineering, University of Wisconsin Madison, Madison, Wisconsin, USA.
Department of Chemistry, University of Wisconsin Madison, Madison, Wisconsin, USA.
Sci Rep. 2018 May 8;8(1):7139. doi: 10.1038/s41598-018-25461-1.
The estrogen receptor (ER) regulates the survival and growth of breast cancer cells, but it is less clear how components of the tissue microenvironment affect ER-mediated responses. We set out to test how human mammary fibroblasts (HMFs) modulate ER signaling and downstream cellular responses. We exposed an organotypic mammary model consisting of a collagen-embedded duct structure lined with MCF7 cells to 17-β estradiol (E2), with and without HMFs in the surrounding matrix. MCF7 cells grown as ductal structures were polarized and proliferated at rates comparable to in vivo breast tissue. In both culture platforms, exposure to E2 increased ER transactivation, increased proliferation, and induced ductal hyperplasia. When the surrounding matrix contained HMFs, the onset and severity of E2-induced ductal hyperplasia was increased due to decreased apoptosis. The reduced apoptosis may be due to fibroblasts modulating ER signaling in MCF7 cells, as suggested by the increased ER transactivation and reduced ER protein in MCF7 cells grown in co-culture. These findings demonstrate the utility of organotypic platforms when studying stromal:epithelial interactions, and add to existing literature that implicate the mammary microenvironment in ER + breast cancer progression.
雌激素受体(ER)调节乳腺癌细胞的存活和生长,但组织微环境的成分如何影响 ER 介导的反应还不太清楚。我们着手测试人乳腺成纤维细胞(HMFs)如何调节 ER 信号转导和下游细胞反应。我们将包含胶原嵌入管结构的器官型乳腺模型与 MCF7 细胞一起暴露于 17-β 雌二醇(E2)中,周围基质中存在和不存在 HMFs。在作为导管结构生长的 MCF7 细胞中,细胞被极化并以与体内乳腺组织相当的速度增殖。在这两种培养平台中,暴露于 E2 增加了 ER 转录激活、增加了增殖并诱导了导管过度增生。当周围基质中含有 HMFs 时,由于细胞凋亡减少,E2 诱导的导管过度增生的开始和严重程度增加。细胞凋亡减少可能是由于成纤维细胞调节 MCF7 细胞中的 ER 信号转导,这正如共培养中生长的 MCF7 细胞中 ER 转录激活增加和 ER 蛋白减少所表明的那样。这些发现证明了器官型平台在研究基质-上皮相互作用时的实用性,并增加了现有文献中关于乳腺微环境在 ER+乳腺癌进展中的作用的证据。
J Exp Clin Cancer Res. 2025-6-16
Health Technol Assess. 2006-9
Cochrane Database Syst Rev. 2008-10-8
Evid Rep Technol Assess (Full Rep). 2009-3
Cochrane Database Syst Rev. 2021-10-29
Breast Cancer Res Treat. 2025-6
Front Oncol. 2024-1-4
Adv Exp Med Biol. 2022
Cancer Metastasis Rev. 2022-9
Micromachines (Basel). 2021-7-12
Clin Cancer Res. 2017-4-1
Toxicol Lett. 2016-4-25
Adv Healthc Mater. 2016-1-21
J Natl Cancer Inst. 2015-3-31
BMC Cancer. 2015-1-21